Blunt dopamine transmission due to decreased GDNF in the PFC evokes cognitive impairment in Parkinson’s disease

Studies have found that the absence of glial cell line-derived neurotrophic factor may be the primary risk factor for Parkinson’s disease. However, there have not been any studies conducted on the potential relationship between glial cell line-derived neurotrophic factor and cognitive performance in Parkinson’s disease. We first performed a retrospective case-control study at the Affiliated Hospital of Xuzhou Medical University between September 2018 and January 2020 and found that a decreased serum level of glial cell line-derived neurotrophic factor was a risk factor for cognitive disorders in patients with Parkinson’s disease. We then established a mouse model of Parkinson’s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and analyzed the potential relationships among glial cell line-derived neurotrophic factor in the prefrontal cortex, dopamine transmission, and cognitive function. Our results showed that decreased glial cell line-derived neurotrophic factor in the prefrontal cortex weakened dopamine release and transmission by upregulating the presynaptic membrane expression of the dopamine transporter, which led to the loss and primitivization of dendritic spines of pyramidal neurons and cognitive impairment. In addition, magnetic resonance imaging data showed that the long-term lack of glial cell line-derived neurotrophic factor reduced the connectivity between the prefrontal cortex and other brain regions, and exogenous glial cell line-derived neurotrophic factor significantly improved this connectivity. These findings suggested that decreased glial cell line-derived neurotrophic factor in the prefrontal cortex leads to neuroplastic degeneration at the level of synaptic connections and circuits, which results in cognitive impairment in patients with Parkinson’s disease.

[1]  J. Andressoo,et al.  The overexpression of GDNF in nucleus accumbens suppresses alcohol-seeking behavior in group-housed C57Bl/6J female mice , 2021, Journal of Biomedical Science.

[2]  M. Eriksdotter,et al.  Increased Endogenous GDNF in Mice Protects Against Age-Related Decline in Neuronal Cholinergic Markers , 2021, Frontiers in Aging Neuroscience.

[3]  Lijing Wang,et al.  Recurrent non-severe hypoglycemia aggravates cognitive decline in diabetes and induces mitochondrial dysfunction in cultured astrocytes , 2021, Molecular and Cellular Endocrinology.

[4]  M. Noroozian,et al.  Do serum GDNF levels correlate with severity of Alzheimer’s disease? , 2020, Neurological Sciences.

[5]  Esther J Pearl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research , 2020, PLoS biology.

[6]  Li Li,et al.  Glial cell line‐derived neurotrophic factor alters lipid composition and protein distribution in MPP+‐injured differentiated SH‐SY5Y cells , 2020, Journal of cellular physiology.

[7]  Yi Liu,et al.  Serum levels of glial cell line‐derived neurotrophic factor and multiple neurotransmitters: In relation to cognitive performance in Parkinson's disease with mild cognitive impairment , 2020, International journal of geriatric psychiatry.

[8]  E. Sieg,et al.  Cognitive Impairment and Dementia in Parkinson Disease. , 2020, Clinics in geriatric medicine.

[9]  Hui-Rong Guo,et al.  Effect of Escitalopram on Serum GDNF and BDNF Levels and 5-HT Level of Brain Tissue of Obsessive–Compulsive Disorder Rats , 2020, Cellular and Molecular Neurobiology.

[10]  L. Olson,et al.  Delayed Dopamine Dysfunction and Motor Deficits in Female Parkinson Model Mice , 2019, International journal of molecular sciences.

[11]  K. Luk,et al.  GDNF/RET signaling pathway activation eliminates Lewy Body pathology in midbrain dopamine neurons , 2019, bioRxiv.

[12]  Xiangrong Zhang,et al.  Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction , 2019, BMC Psychiatry.

[13]  Chuan-xi Tang,et al.  Meta-Analysis of the Effects of the Catechol-O-Methyltransferase Val158/108Met Polymorphism on Parkinson’s Disease Susceptibility and Cognitive Dysfunction , 2019, Front. Genet..

[14]  Alex D. Bird,et al.  Dissecting Sholl Analysis into Its Functional Components. , 2019, Cell reports.

[15]  Ilana B. Witten,et al.  Dopamine modulation of prefrontal cortex activity is manifold and operates at multiple temporal and spatial scales , 2018, bioRxiv.

[16]  Hyun-Ok Yang,et al.  Cerebrospinal Fluid Levels of Autophagy-related Proteins Represent Potentially Novel Biomarkers of Early-Stage Parkinson’s Disease , 2018, Scientific Reports.

[17]  Anatol C. Kreitzer,et al.  A Genetically Encoded Fluorescent Sensor Enables Rapid and Specific Detection of Dopamine in Flies, Fish, and Mice , 2018, Cell.

[18]  L. Nyberg.  Cognitive control in the prefrontal cortex: A central or distributed executive? , 2018, Scandinavian journal of psychology.

[19]  Chan Chen,et al.  Serum glial cell line–derived neurotrophic factor levels and postoperative cognitive dysfunction after surgery for rheumatic heart disease , 2017, The Journal of thoracic and cardiovascular surgery.

[20]  A. Dagher,et al.  Effects of levodopa on corticostriatal circuits supporting working memory in Parkinson's disease , 2017, Cortex.

[21]  D. Souza,et al.  Hippocampal Astrocyte Cultures from Adult and Aged Rats Reproduce Changes in Glial Functionality Observed in the Aging Brain , 2016, Molecular Neurobiology.

[22]  Wenjun Gao,et al.  Norepinephrine versus dopamine and their interaction in modulating synaptic function in the prefrontal cortex , 2016, Brain Research.

[23]  M. Poo,et al.  Phasic dopamine release in the medial prefrontal cortex enhances stimulus discrimination , 2016, Proceedings of the National Academy of Sciences.

[24]  L. Tenenbaum,et al.  Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system , 2016, Neurobiology of Disease.

[25]  Ian C. Ballard,et al.  Hippocampus and Prefrontal Cortex Predict Distinct Timescales of Activation in the Human Ventral Tegmental Area , 2016, Cerebral cortex.

[26]  Beate Ritz,et al.  People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance , 2014, Movement disorders : official journal of the Movement Disorder Society.

[27]  T. Robbins,et al.  Introduction: The importance of cognition in movement disorders , 2014, Movement disorders : official journal of the Movement Disorder Society.

[28]  C. Adler,et al.  The neurobiological basis of cognitive impairment in Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[29]  Arthur W Toga,et al.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. , 2013, JAMA neurology.

[30]  Jing Zhang,et al.  Biomarkers of Parkinson's disease: current status and future perspectives. , 2013, Drug discovery today.

[31]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[32]  C. Meshul,et al.  Profiling changes in gait dynamics resulting from progressive 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced nigrostriatal lesioning , 2011, Journal of neuroscience research.

[33]  I. Kirsch.  Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. Preface. , 2011, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[34]  C. Clarke,et al.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[35]  Satoru Otani,et al.  Functional and Dysfunctional Synaptic Plasticity in Prefrontal Cortex: Roles in Psychiatric Disorders , 2010, Biological Psychiatry.

[36]  W. Gan,et al.  Stably maintained dendritic spines are associated with lifelong memories , 2009, Nature.

[37]  R. Bartesaghi,et al.  Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood , 2009, Hippocampus.

[38]  D. Feldman.  Synaptic mechanisms for plasticity in neocortex. , 2009, Annual review of neuroscience.

[39]  T. Rubino,et al.  The Depressive Phenotype Induced in Adult Female Rats by Adolescent Exposure to THC is Associated with Cognitive Impairment and Altered Neuroplasticity in the Prefrontal Cortex , 2009, Neurotoxicity Research.

[40]  J. Jankovic.  Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[41]  D. Brooks,et al.  Extrastriatal monoamine neuron function in Parkinson’s disease: An 18F-dopa PET study , 2008, Neurobiology of Disease.

[42]  A. Hoffman,et al.  MPTP‐induced deficits in striatal synaptic plasticity are prevented by glial cell line‐derived neurotrophic factor expressed via an adeno‐associated viral vector , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.

[44]  M. Saarma,et al.  Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo , 2007, Nature.

[45]  T. Robbins,et al.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. , 2007, Brain : a journal of neurology.

[46]  S. Nicola.  The nucleus accumbens as part of a basal ganglia action selection circuit , 2007, Psychopharmacology.

[47]  Philip D. Harvey,et al.  Administration and interpretation of the Trail Making Test , 2006, Nature Protocols.

[48]  P. Gean,et al.  Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes , 2006, Molecular Psychiatry.

[49]  T. Tokuda,et al.  Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. , 2006 .

[50]  Y. Terayama,et al.  Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. , 2005, Life sciences.

[51]  S. Sahadevan,et al.  Clinical Dementia Rating: Experience of a Multi-Racial Asian Population , 2005, Alzheimer disease and associated disorders.

[52]  J. Lanciego,et al.  Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells , 2005, The European journal of neuroscience.

[53]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[54]  A. Sorkin,et al.  Constitutive and Protein Kinase C‐Induced Internalization of the Dopamine Transporter is Mediated by a Clathrin‐Dependent Mechanism , 2005, Traffic.

[55]  A. Grace,et al.  The Catechol-O-Methyltransferase Polymorphism: Relations to the Tonic–Phasic Dopamine Hypothesis and Neuropsychiatric Phenotypes , 2004, Neuropsychopharmacology.

[56]  Steven W. Johnson,et al.  GDNF acutely modulates excitability and A-type K+ channels in midbrain dopaminergic neurons , 2001, Nature Neuroscience.

[57]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[58]  T. Sejnowski,et al.  Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex. , 2000, Journal of neurophysiology.

[59]  P. Aebischer,et al.  Neuronal GDNF Expression in the Adult Rat Nervous System Identified By In Situ Hybridization , 1997, The European journal of neuroscience.

[60]  L. Olson,et al.  Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[61]  C. Olanow,et al.  The pathogenesis of cell death in Parkinson's disease – 2007 , 2007, Movement disorders : official journal of the Movement Disorder Society.

[62]  E. Miller,et al.  An integrative theory of prefrontal cortex function. , 2001, Annual review of neuroscience.